0 47

Cited 156 times in

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial

Authors
 Randolph Hecht  ;  Yung-Jue Bang  ;  Shukui K. Qin  ;  Hyun C. Chung  ;  Jianming M. Xu  ;  Joon O. Park  ;  Krzysztof Jeziorski  ;  Yaroslav Shparyk  ;  Paulo M. Hoff  ;  Alberto Sobrero  ;  Pamela Salman  ;  Jin Li  ;  Svetlana A. Protsenko  ;  Zev A. Wainberg  ;  Marc Buyse  ;  Karen Afenjar  ;  Vincent Hou?  ;  Agathe Garcia  ;  Tomomi Kaneko  ;  Yingjie Huang  ;  Saba Khan-Wasti  ;  Sergio Santillana  ;  Michael F. Press  ;  Dennis Slamon 
Citation
 Journal of Clinical Oncology, Vol.34(5) : 443-451, 2016 
Journal Title
 Journal of Clinical Oncology 
ISSN
 0732-183X 
Issue Date
2016
MeSH
Adenocarcinoma/drug therapy* ; Adenocarcinoma/genetics ; Adenocarcinoma/mortality ; Adenocarcinoma/secondary ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Biomarkers, Tumor/genetics* ; Capecitabine/administration & dosage ; Double-Blind Method ; Esophageal Neoplasms/drug therapy* ; Esophageal Neoplasms/genetics ; Esophageal Neoplasms/mortality ; Esophageal Neoplasms/pathology ; Esophagogastric Junction/drug effects* ; Esophagogastric Junction/pathology ; Female ; Follow-Up Studies ; Gene Amplification ; Humans ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Staging ; Organoplatinum Compounds/administration & dosage ; Polymerase Chain Reaction ; Prognosis ; Quinazolines/administration & dosage ; Receptor, ErbB-2/genetics* ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/genetics ; Stomach Neoplasms/mortality ; Stomach Neoplasms/pathology ; Survival Rate ; Young Adult
Abstract
PURPOSE: To evaluate the efficacy of adding lapatinib to capecitabine and oxaliplatin (CapeOx) in patients with previously untreated human epidermal growth factor receptor 2 (HER2) -amplified advanced gastroesophageal adenocarcinoma. PATIENTS AND METHODS: Patients with HER2-positive advanced gastroesophageal adenocarcinoma were randomly assigned at a one-to-one ratio to CapeOx plus lapatinib 1,250 mg or placebo daily. Primary end point was overall survival (OS) in patients with centrally confirmed HER2 amplification in the primary efficacy population. RESULTS: A total of 545 patients were randomly assigned, and 487 patients comprised the primary efficacy population. Median OS in the lapatinib and placebo arms was 12.2 (95% CI, 10.6 to 14.2) and 10.5 months (95% CI, 9.0 to 11.3), respectively, which was not significantly different (hazard ratio, 0.91; 95% CI, 0.73 to 1.12). Median progression-free survival in the lapatinib and placebo arms was 6.0 (95% CI, 5.6 to 7.0) and 5.4 months (95% CI, 4.4 to 5.7), respectively (hazard ratio, 0.82; 95% CI, 0.68 to 1.00; P = .0381). Response rate was significantly higher in the lapatinib arm: 53% (95% CI, 46.4 to 58.8) compared with 39% (95% CI, 32.9 to 45.3) in the placebo arm (P = .0031). Preplanned exploratory subgroup analyses showed OS in the lapatinib arm was prolonged in Asian and younger patients. No correlation was observed between HER2 immunohistochemistry status and survival. There were increased toxicities in the lapatinib arm, particularly diarrhea. CONCLUSION: Addition of lapatinib to CapeOx did not increase OS in patients with HER2-amplified gastroesophageal adenocarcinoma. There were clear differences in the effect of lapatinib depending on region and age. Future studies could examine this correlation.
Full Text
http://ascopubs.org/doi/abs/10.1200/JCO.2015.62.6598
DOI
10.1200/JCO.2015.62.6598
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
정현철(Chung, Hyun Cheol) ORCID logo https://orcid.org/0000-0002-0920-9471
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/151690
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse